Protein

Alterome Therapeutics Raises $132 Million in Series B Financing Led by Goldman Sachs Alternatives

Retrieved on: 
Wednesday, April 3, 2024
Research, Finance, Clinical Trials, Professional Services, Biotechnology, Health, General Health, Science, Oncology, OrbiMed, Drug discovery, Patient, Cancer, Sachs, Blue Owl Capital, Protein, Medicine, Richard Driehaus, Therapy, Partner

Alterome Therapeutics, Inc. , a biopharmaceutical company pioneering the development of next generation, small molecule targeted therapies for the treatment of cancer, today announced the closing of a $132 million Series B financing.

Key Points: 
  • Alterome Therapeutics, Inc. , a biopharmaceutical company pioneering the development of next generation, small molecule targeted therapies for the treatment of cancer, today announced the closing of a $132 million Series B financing.
  • The financing was led by Goldman Sachs Alternatives, with participation by Canaan Partners, Invus, Driehaus Capital Management, Digitalis Ventures, Blue Owl Capital, and existing investors Orbimed, Nextech Invest, Vida Ventures, Boxer Capital, and Colt Ventures.
  • Concurrent with the financing, Josh Richardson, M.D., a Managing Director within Life Sciences Investing at Goldman Sachs Alternatives, and Uwe Schoenbeck, a Partner at Canaan Partners, were named to the Board of Directors.
  • “Alterome is advancing an exciting portfolio of therapies targeting validated oncogenic drivers, with clear paths to early clinical signals,” said Dr. Josh Richardson, Managing Director within Life Sciences Investing at Goldman Sachs Alternatives.

Global Biodegradable Microbeads Market Report 2024, with Profiles of Ajinomoto, Andritz, Asahi Kasei, BASF, Bioweg, CELLiCON, Croda, Daicel, Green Science, Lactips, LignoPure, Naturbeads and More - ResearchAndMarkets.com

Retrieved on: 
Monday, April 1, 2024
Cosmetics, Retail, Chemicals, Plastics, Oil, Gas, Manufacturing, Energy, Polysaccharide, Microplastics, BASF, Market, Asahi Kasei, Health, Agriculture, Research, Classification, Polyester, Food, Detergent, Protein, Skin, Drink, USD

The "Global Market for Biodegradable Microbeads 2024-2035" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Market for Biodegradable Microbeads 2024-2035" report has been added to ResearchAndMarkets.com's offering.
  • Plastic microbeads are a multi-billion dollar market, with applications in markets ranging from cosmetics to oil & gas.
  • Replacement of plastic microbeads with biodegradable and non-toxic alternatives is increasingly important and the market will grow to meet both regulatory demands and increased use of microbeads in healthcare (e.g.
  • Many companies have curtailed their use or pivoted to natural alternatives, but it still represents a sizeable global market.

Global Immune Health Supplements Outlook Report 2024: Market to Reach $34.73 Billion by 2028 with Amway, Bayer, DSM, Glanbia, Herbalife Nutrition, and Nutramax Laboratories Dominating - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 28, 2024
Vitamins, Supplements, Health, Capsule, Dicarboxylic acid, Attention, Bayer, Vitamin, Growth, Prevalence, Vitamin D, Infection, Amway, Dietary supplement, Printing, Probiotic, COVID-19, Zinc, DSM, Tablet, Calcium, Pharmacy, Selenium, Ageing, Pregnancy, Mineral, Protein, Mineral deficiency, Woman, Nutritional science, Immunity, Wound healing, Iron, Nutraceutical, Herbalife, Herbal, Supermarket

The global immune health supplements market was valued at $20.80 billion in 2022 and is expected to reach $34.73 billion by 2028, growing at a CAGR of 8.92%

Key Points: 
  • The global immune health supplements market was valued at $20.80 billion in 2022 and is expected to reach $34.73 billion by 2028, growing at a CAGR of 8.92%
    The global immune health supplements market is witnessing several dynamic changes after the Coronavirus surge worldwide.
  • In the global immune health supplements market, several leading domestic, national, and international vendors are present.
  • North America accounted for the highest global immune health supplements market share, accounting for over 33% in 2022.
  • High Demand for Immune Health Supplements with Zinc, Vitamin C & D, and Curcumins
    In the immune health supplements market, vitamin C, vitamin D, zinc, and curcumins are the most used and suggested ingredients for immune health.

MyBio Are the New Exclusive Partner for QIAGEN in Ireland & Northern Ireland

Retrieved on: 
Wednesday, March 27, 2024
Research, Public Policy, Government, Other Natural Resources, Biotechnology, White House, Federal Government, Health, Agriculture, Natural Resources, Science, Other Science, Partnership, HID, RNA, DNA, IVD, QDI, Protein, QIAGEN, Collection, Marketing

MyBio Ltd., an award-winning specialist Irish life science distribution partner, announces a new exclusive partnership with QIAGEN, a leading global provider, to distribute their leading Life Science “Sample to Insight” product range throughout Ireland and Northern Ireland with effect from April 1st, 2024.

Key Points: 
  • MyBio Ltd., an award-winning specialist Irish life science distribution partner, announces a new exclusive partnership with QIAGEN, a leading global provider, to distribute their leading Life Science “Sample to Insight” product range throughout Ireland and Northern Ireland with effect from April 1st, 2024.
  • This exclusivity refers to Life Science products for the respective customer base and does not extend to other product portfolios of QIAGEN such as IVD regulated products, HID, Instrument Service or QDI products or customer segments.
  • This new partnership extends QIAGEN’S reach into the Irish life science market by leveraging MyBio Ltd.’s strong commercial presence and deep ties within the Academic, Biopharma and Agri-Bioscience industries in Ireland and Northern Ireland.
  • Under the terms of the agreement, MyBio Ltd. will exclusively supply the QIAGEN Life Science research product range to the academic research, biopharma, and agri-bioscience industries across the Island of Ireland.

National Geographic Magazine Showcases NanoString’s Spatial Biology Technology to Examine Cell Death in Alzheimer’s Disease

Retrieved on: 
Wednesday, March 27, 2024
Seniors, Nanotechnology, Research, Software, Medical Devices, Hardware, Consumer, Genetics, Professional Services, Science, Technology, Clinical Trials, Publishing, Data Analytics, Biotechnology, Health, Communications, Health Technology, National Geographic, MicroRNA, Brain, Gene, Myenteric plexus, Gene expression, NanoString Technologies, Cell, Disease, Memory, Alzheimer's disease, Tau, Risk, Hippocampus, Inflammation, Patient, RNA, News, Federal republic, Protein, Biology, Proteomics, Publication, OTC, Ecosystem, Multimedia, SMI, Ageing

When blue, magenta, and green all appear in a cell, especially a large cell, that's evidence it is a zombie cell.

Key Points: 
  • When blue, magenta, and green all appear in a cell, especially a large cell, that's evidence it is a zombie cell.
  • (Graphic: NanoString)
    A special-interest magazine from National Geographic called Anti-Inflammation, available on newsstands this week, spotlights the role of inflammation on health and disease.
  • NanoString Technologies, a leader in spatial biology, offers an ecosystem of innovative discovery and translational research solutions, empowering our customers to map the universe of biology.
  • The AtoMx™ Spatial Informatics Platform is a cloud-based informatics solution with advanced analytics and global collaboration capabilities, enabling powerful spatial biology insights anytime, anywhere.

Texas Original Announces Opening of Sugar Land Location, Launches New RSO Gummies

Retrieved on: 
Wednesday, March 27, 2024
Vitamins, Supplements, Tobacco, Cannabis, Alternative Medicine, General Health, Pharmaceutical, Health, Retail, Natural Resources, Oncology, Dark, Epilepsy, Spasticity, Cannabinoid, RSO, Patient, Flavonoid, Cancer, Terpene, Protein, Originality, THC, Physician, PTSD, Diabetic neuropathy, Medicinal plants

Texas Original , Texas’ leading medical cannabis provider, today announced the opening of its newest prescription pickup location in Sugar Land, Texas.

Key Points: 
  • Texas Original , Texas’ leading medical cannabis provider, today announced the opening of its newest prescription pickup location in Sugar Land, Texas.
  • Texas Original also announced the launch of its new Pineapple Gummies, a 20 mg THC-only product made with Rick Simpson Oil (RSO).
  • Alongside the company’s recently launched Dark Chocolate Bites and RSO Tincture, Texas Original’s Pineapple Gummies are among the first medical cannabis products in the state—and the first gummy product—to incorporate RSO.
  • Texans can obtain medical cannabis prescriptions through online clinics or local physicians registered with the Compassionate Use Registry of Texas.

Peer-Reviewed Scientific Publication Proposes Unifying Single Toxin Theory of Brain Neurodegeneration that Identifies New Drug Targets and Treatments for Alzheimer’s Disease and Other Neurodegenerative Disorders

Retrieved on: 
Tuesday, March 26, 2024
Health, Neurology, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Toxicity, Brain, DSM-IV codes, APOE4, Patient, Biomarker, NDA, Standard of care, Prion, Doctor of Philosophy, MD, Protein, Neurotoxicity, Genotype, Treatment, Safety, ALS, Canadian International Council, Amyloid

In addition, our single toxin theory of brain neurodegeneration identifies new targets and approaches for the development of disease-modifying treatments,” said Martin Tolar, MD, PhD, Founder, President, and CEO of Alzheon.

Key Points: 
  • In addition, our single toxin theory of brain neurodegeneration identifies new targets and approaches for the development of disease-modifying treatments,” said Martin Tolar, MD, PhD, Founder, President, and CEO of Alzheon.
  • The application of biomarkers, in particular p-tau, synaptic markers, and brain volumetrics for the evaluation of disease course and therapeutic efficacy in AD trials.
  • Other neurodegenerative disorders follow the same pattern of protein dysregulation, impaired clearance, and increased aggregation, leading to neurotoxicity and loss of function.
  • In these diseases, a normal essential protein starts accumulating in the brain, misfolding and aggregating into soluble oligomers.

New Findings From Sunbird Bio Reveal Significant Potential of Specific Tau Proteins to Serve as Blood-Based Biomarker for Alzheimer’s Disease

Retrieved on: 
Monday, March 25, 2024
Oncology, Health, Neurology, General Health, Research, Science, Biotechnology, Diagnosis, EV, Brain, Plasma, Conference, Dementia, EVS, CSF, Tau, Alzheimer's disease, Sunbird, AUC, Patient, PET, Biomarker, Traffic barrier, APEX, Cerebrospinal fluid, Protein, Neuron, Trial of the century, Aggregation, DSM-IV codes, Blood, Medical imaging

“These results validate the potential of EV-bound tau proteins to serve as reliable blood-based biomarkers in accurately detecting Alzheimer’s disease,” said John McDonough, executive chair and CEO of Sunbird Bio.

Key Points: 
  • “These results validate the potential of EV-bound tau proteins to serve as reliable blood-based biomarkers in accurately detecting Alzheimer’s disease,” said John McDonough, executive chair and CEO of Sunbird Bio.
  • “This confirmed correlation between EV-bound tau in the blood and tau tangles in the brain combined with the early validation of our new tau assays is incredibly exciting.
  • The Sunbird Bio study being shared at Tau2024 evaluated the potential of EV-bound tau proteins in the blood as a method of directly detecting the tau proteins that aggregate in the brain.
  • They then used Sunbird Bio’s new proprietary tau assays to distinguish between EV-bound and unbound soluble forms of tau in plasma.

Celanese and Secarna Pharmaceuticals Enter into RNA Research Collaboration for Long-Acting Antisense Therapies

Retrieved on: 
Wednesday, March 20, 2024
Research, General Health, Pharmaceutical, Oncology, Data Management, Technology, Infectious Diseases, Science, Chemicals, Plastics, Biotechnology, Manufacturing, Health, CE, Asos, Drug discovery, Central nervous system, Patient, Corporation, Ophthalmology, RNA, CBO, Protein, Drug development, Medical device

Celanese Corporation (NYSE: CE), a global specialty materials and chemical company, and Secarna Pharmaceuticals GmbH & Co. KG, a leading independent European antisense drug discovery and development company, today announced a research collaboration for the development of long-acting implants that deliver antisense oligonucleotides (ASOs).

Key Points: 
  • Celanese Corporation (NYSE: CE), a global specialty materials and chemical company, and Secarna Pharmaceuticals GmbH & Co. KG, a leading independent European antisense drug discovery and development company, today announced a research collaboration for the development of long-acting implants that deliver antisense oligonucleotides (ASOs).
  • “Collaborating with Secarna allows us to develop an innovative implant that has the potential to significantly change the way disease-modifying ASO therapies are administered,” said Cyonna Holmes, global business strategy leader for Ophthalmology and RNA at Celanese.
  • With several high value and innovative programs, Secarna has validated its platform in various indications such as cardiometabolic, immune-oncology, fibrotic/inflammatory diseases and the central nervous system.
  • “We are looking forward to partnering with Celanese to combine our industry-leading ASO platform with their VitalDose® drug delivery technology,” said Konstantin Petropoulos, CBO of Secarna Pharmaceuticals.

Global Sardine Market to Reach 4.0 Million Tons by 2032, Driven by Nutritional Awareness and Sustainable Fishing - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 20, 2024
Food, Beverage, Retail, Protein, COVID-19, Market, Research, Taste, Growth, Supermarket, Aquaculture

Reflecting on the market size, the global sardine market scaled 3.6 million tons in 2023.

Key Points: 
  • Reflecting on the market size, the global sardine market scaled 3.6 million tons in 2023.
  • Coupled with evolving dietary preferences and the convenience offered by various sardine products, the market's potential continues to surge.
  • Moreover, the research highlights the accelerating impact of e-commerce platforms on the sardine industry, fostering greater accessibility and customer reach.
  • Environmental conservation efforts have significantly influenced the sardine market, with sustainable fishing practices and regulations ensuring responsible resource exploitation.